These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 7753139

  • 1. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
    Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF.
    N Engl J Med; 1995 Jun 15; 332(24):1606-10. PubMed ID: 7753139
    [Abstract] [Full Text] [Related]

  • 2. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
    Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF.
    N Engl J Med; 1993 Jan 14; 328(2):81-6. PubMed ID: 7677966
    [Abstract] [Full Text] [Related]

  • 3. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 4. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.
    Perrine SP, Olivieri NF, Faller DV, Vichinsky EP, Dover GJ, Ginder GD.
    Am J Pediatr Hematol Oncol; 1994 Feb 14; 16(1):67-71. PubMed ID: 7508690
    [Abstract] [Full Text] [Related]

  • 5. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.
    Griffin TC, McIntire D, Buchanan GR.
    N Engl J Med; 1994 Mar 17; 330(11):733-7. PubMed ID: 8107739
    [Abstract] [Full Text] [Related]

  • 6. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease.
    Wilimas JA, Flynn PM, Harris S, Day SW, Smith R, Chesney PJ, Rodman JH, Eguiguren JM, Fairclough DL, Wang WC.
    N Engl J Med; 1993 Aug 12; 329(7):472-6. PubMed ID: 8332152
    [Abstract] [Full Text] [Related]

  • 7. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia.
    Embury SH, Dozy AM, Miller J, Davis JR, Kleman KM, Preisler H, Vichinsky E, Lande WN, Lubin BH, Kan YW, Mentzer WC.
    N Engl J Med; 1982 Feb 04; 306(5):270-4. PubMed ID: 6172710
    [Abstract] [Full Text] [Related]

  • 8. Reversing ontogeny.
    Bunn HF.
    N Engl J Med; 1993 Jan 14; 328(2):129-31. PubMed ID: 7677964
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 14; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 11. Pain in sickle cell disease. Rates and risk factors.
    Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR.
    N Engl J Med; 1991 Jul 04; 325(1):11-6. PubMed ID: 1710777
    [Abstract] [Full Text] [Related]

  • 12. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
    Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1990 Apr 12; 322(15):1037-45. PubMed ID: 1690857
    [Abstract] [Full Text] [Related]

  • 13. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Dec 12; 435():1-288. PubMed ID: 12595928
    [Abstract] [Full Text] [Related]

  • 14. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 12; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 15. Molecular biology of hemoglobin: its application to sickle cell anemia and thalassemia.
    Kan YW.
    Schweiz Med Wochenschr Suppl; 1991 Sep 12; 43():51-4. PubMed ID: 1726857
    [Abstract] [Full Text] [Related]

  • 16. The interaction of alpha-thalassemia and homozygous sickle-cell disease.
    Higgs DR, Aldridge BE, Lamb J, Clegg JB, Weatherall DJ, Hayes RJ, Grandison Y, Lowrie Y, Mason KP, Serjeant BE, Serjeant GR.
    N Engl J Med; 1982 Jun 17; 306(24):1441-6. PubMed ID: 6176865
    [Abstract] [Full Text] [Related]

  • 17. Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.
    Fathallah H, Taher A, Bazarbachi A, Atweh GF.
    Blood Cells Mol Dis; 2009 Jun 17; 43(1):58-62. PubMed ID: 19346141
    [Abstract] [Full Text] [Related]

  • 18. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
    Mtvarelidze Z, Kvezereli-Kopadze A, Kvezereli-Kopadze M, Mestiashvili I.
    Georgian Med News; 2008 Mar 17; (156):91-4. PubMed ID: 18403819
    [Abstract] [Full Text] [Related]

  • 19. Sickle cell disease as a cause of osteonecrosis of the femoral head.
    Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, Bellevue R, Koshy M, Moohr JW, Smith J.
    N Engl J Med; 1991 Nov 21; 325(21):1476-81. PubMed ID: 1944426
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.